Bionovo's Drug Candidate for Menopausal Symptoms Shows Effect on
Neural Pathways Related to Temperature Regulation
- Results Presented at Endocrine Society 90th Annual Meeting -
SAN FRANCISCO and EMERYVILLE, Calif., June 16 /PRNewswire-
FirstCall/ --
Bionovo Inc. (Nasdaq: BNVI) today announced results from in vitro
studies
in neurons of its drug candidate, MF101. The data were presented at
the
Endocrine Society 90th Annual Meeting. Bionovo showed that, in neurons
differentiated from mouse stem cells and expressing native estrogen
receptors, MF101, an estrogen receptor beta selective modulator,
regulated
calcium levels, which are related to temperature regulation.
"Menopausal hot flashes occur in approximately 80% of menopausal
women," said Dr. Dale Leitman, from the Department of Obstetrics,
Gynecology and Reproductive Sciences at the University of California,
San
Francisco. "It has long been known that estrogens reduce hot flashes
and
non-selective SERMs cause hot flashes. However, there have not been
appropriate cell-based models to screen estrogens for effects on
neurons.
This study demonstrated that changes in calcium levels in neurons, an
important biochemical pathway to temperature regulation, are mediated
selectively by the activation of estrogen receptor beta. MF101
demonstrated
this selective regulation."
The study was conducted by investigators at The Center for
Reproductive
Sciences in the Department of Obstetrics, Gynecology and Reproductive
Sciences at the University of California, San Francisco in
collaboration
with scientists at Bionovo.
"Although estrogens are very effective in the treatment of
menopausal
hot flashes, they have been associated with many serious health
risks, such
as breast and uterine cancer," said Isaac Cohen, Bionovo's chairman
and
chief executive officer. "In a Phase 2 clinical trial, MF101, our
selective
estrogen receptor beta modulator, was effective in the treatment of
hot
flashes. But unlike estrogen, it did not adversely effect the uterus.
This
study provides a further mechanistic explanation to the observed
clinical
results. We believe that the efficacy coupled with improved safety of
MF101
over current estrogen treatment will be greatly welcomed by women
going
through menopause. The results also demonstrate Bionovo's robust
science
for its pipeline under development for women's health."
About MF101
MF101 is an estrogen receptor beta (ER-b) selective drug for the
treatment of menopausal hot flashes, developed as an alternative to
those
products currently on the market, which have been shown to increase
the
risk for breast and uterine cancers. It has been shown that the
increased
risk of breast and uterine cancers is associated with estrogen
receptor
alpha (ER-a) activation and that estrogen receptor beta (ER-b) blocks
the
growth promoting effects on breast cancer cells. Bionovo recognized
the
opportunity to commercialize a product that would be equally
effective,
with an improved safety profile to hormone therapy. The drug
candidate has
been evaluated by an independent Data and Safety Monitoring Board and
has
passed through a standard two-round examination for safety.
Bionovo, Inc.
Bionovo is a pharmaceutical company focused on the discovery and
development of safe and effective treatments for women's health and
cancer,
which are markets with significant unmet needs and billions in
potential
annual revenue. The company applies its expertise in the biology of
menopause and cancer to design new drugs derived from botanical
sources
which have novel mechanisms of action. Based on the results of early
and
mid-stage clinical trials, Bionovo believes they have discovered new
classes of drug candidates within their rich pipeline with the
potential to
be leaders in their markets. Bionovo is headquartered in Emeryville,
California and is traded on the NASDAQ Capital Market under the
symbol,
"BNVI". For more information about Bionovo and its programs, visit
http://www.bionovo.
Forward Looking Statements
This release contains certain forward-looking statements relating
to
the business of Bionovo, Inc. that can be identified by the use of
forward-looking terminology such as "believes," "expects," or similar
expressions. Such forward-looking statements involve known and unknown
risks and uncertainties, including uncertainties relating to product
development, efficacy and safety, regulatory actions or delays, the
ability
to obtain or maintain patent or other proprietary intellectual
property
protection, market acceptance, physician acceptance, third party
reimbursement, future capital requirements, competition in general and
other factors that may cause actual results to be materially
different from
those described herein as anticipated, believed, estimated or
expected.
Certain of these risks and uncertainties are or will be described in
greater detail in our filings with the Securities and Exchange
Commission,
which are available at http://www.sec.
obligation (and expressly disclaims any such obligation) to update or
alter
its forward-looking statements whether as a result of new information,
future events or otherwise.
SOURCE Bionovo Inc.
http://www.prnewswi
ACCT=104&STORY=
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
No comments:
Post a Comment